Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Purine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL1705518 | 0.91 | ALDH1A1 (0.37) | CHEK1PDPK1MAPK1PAK1RXFP1 | |
| Triphosphate SCHEMBL9104232 | 0.90 | P2RX3 (0.36) | — | |
| Purine SCHEMBL595231 | 0.88 | ALDH1A1 (0.39) | CHEK1PDPK1PAK1RXFP1ALDH1A1 | |
| Purine SCHEMBL27554272 | 0.88 | ALDH1A1 (0.39) | CHEK1PDPK1PAK1RXFP1ALDH1A1 | |
| Purine SCHEMBL5989434 | 0.88 | ALDH1A1 (0.39) | CHEK1PDPK1PAK1RXFP1ALDH1A1 | |
| Purine SCHEMBL2676962 | 0.82 | ALDH1A1 (0.41) | RXFP1ALDH1A1KDM4EENPP1 | |
| Purine SCHEMBL7453138 | 0.79 | ALDH1A1 (0.33) | RXFP1ALDH1A1KDM4E | |
| Purine SCHEMBL7453075 | 0.79 | ALDH1A1 (0.33) | RXFP1ALDH1A1KDM4E | |
| Purine SCHEMBL28190001 | 0.79 | ALDH1A1 (0.45) | CHEK1PDPK1MAPK1PAK1RXFP1 | |
| Purine SCHEMBL27636167 | 0.79 | ALDH1A1 (0.45) | CHEK1PDPK1MAPK1PAK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012078416-A2 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | RFS PHARMA, LLC (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | EMORY UNIVERSITY (US) | 2012-06-07 | — | — | US | disclosed |
| EP-0688796-A1 | Reaction products of polyetheramines with polymers of alpha, beta- unsaturated dicarboxylic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | DCTD, ENTPD5, PNP | CHEK1 1318/4885PDPK1 1010/4885MAPK1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.